{"abstract": "Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.", "web_url": "https://www.nytimes.com/2015/10/30/business/dealbook/pfizer-faces-challenges-in-pursuing-deal-for-a-lower-tax-rate.html", "snippet": "Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.", "lead_paragraph": "There\u2019s no easy cure for tax.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "height": 508, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 508}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-jumbo.jpg", "height": 867, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-superJumbo.jpg", "height": 1253, "width": 1480, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Faces Challenges in Pursuing Deal for a Lower Tax Rate", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 7, "major": "N"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "rank": 8, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 9, "major": "N"}], "pub_date": "2015-10-29T16:43:38+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By John Foley", "person": [{"firstname": "John", "middlename": null, "lastname": "Foley", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4de024c5-722c-52a2-8e12-bdb90b4efdc4", "word_count": 401, "uri": "nyt://article/4de024c5-722c-52a2-8e12-bdb90b4efdc4"}